RT Journal Article
SR Electronic
T1 The complex interplay between risk tolerance and the spread of infectious diseases
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.07.01.24309771
DO 10.1101/2024.07.01.24309771
A1 Nguyen, Maximilian
A1 Freedman, Ari
A1 Cheung, Matthew
A1 Saad-Roy, Chadi
A1 Espinoza, Baltazar
A1 Grenfell, Bryan
A1 Levin, Simon
YR 2024
UL http://medrxiv.org/content/early/2024/09/18/2024.07.01.24309771.abstract
AB Risk-driven behavior provides a feedback mechanism through which individuals both shape and are collectively affected by an epidemic. We introduce a general and flexible compartmental model to study the effect of heterogeneity in the population with regards to risk tolerance. The interplay between behavior and epidemiology leads to a rich set of possible epidemic dynamics. Depending on the behavioral composition of the population, we find that increasing heterogeneity in risk tolerance can either increase or decrease the epidemic size. We find that multiple waves of infection can arise due to the interplay between transmission and behavior, even without the replenishment of susceptibles. We find that increasing protective mechanisms such as the effectiveness of interventions, the number of risk-averse people in the population, and the duration of intervention usage reduces the epidemic overshoot. When the protection is pushed past a critical threshold, the epidemic dynamics enter an underdamped regime where the epidemic size exactly equals the herd immunity threshold and overshoot is eliminated. Lastly, we can find regimes where epidemic size does not monotonically decrease with a population that becomes increasingly risk-averse.Competing Interest StatementThe authors have declared no competing interest.Funding StatementM.M.N., A.S.F., M.A.C., and S.A.L. would like to acknowledge funding from NSF (CCF1917819, CNS-2041952, DMS-2327711), Army Research Office (W911NF-18-1-0325), and a gift from William H. Miller III. C.M.S.-R. acknowledges funding from the Miller Institute for Basic Research in Science of UC Berkeley via a Miller Research Fellowship. B.E.C. would like to acknowledge funding from NSF (IHBEM grant 2327710 and Expeditions NSF 1918656). B.T.G. would like to acknowledge the Princeton Catalysis Initiative and Princeton Precision Medicine.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All data are generated via simulation and included in manuscript.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes